Terconazole
Pronouncation: (ter-CONE-uh-zole)Class: Vaginal antifungal agent
Trade Names:
Terazole 3
- Vaginal cream 0.8%
- Vaginal suppositories 80 mg
Trade Names:
Terazole 7
- Vaginal cream 0.4%
Pharmacology
 | ||||||
Feedback for Terconazole
Compare with other drugs. | ||||||
May alter permeability of fungus cell membrane, allowing leakage of essential intracellular components.
Pharmacokinetics
Absorption
Terconazole C max is approximately 5.9 ng/mL or 0.006 mcg/mL and T max is about 6.6 h.
Distribution
Terconazole is 94.9% protein bound. The degree of binding is independent of the drug concentration.
Metabolism
Terconazole is extensively metabolized.
Elimination
Terconazole t ½ is 6.9 h (range, 4 to 11.3 h). Excretion of radioactivity is by both renal (32% to 56%) and fecal (47% to 52%) routes.
Special Populations
GenderFollowing terconazole administration, absorption varies in hysterectomized subjects (5% to 8% absorption) vs nonhysterectomized subjects (12% to 16% absorption). Other than this, overall absorption is similar in all women.
Indications and Usage
Local treatment of vulvovaginal candidiasis.
Contraindications
Standard considerations.
Dosage and Administration
AdultsIntravaginal 1 suppository at bedtime for 3 days or 1 applicatorful of 0.4% cream at bedtime for 7ߙdays or 1 applicatorful of 0.8% cream for 3 days.
Storage/Stability
Store at room temperature.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Headache.
GI
Abdominal pain.
Genitourinary
Dysmenorrhea; genitalia pain; vulvovaginal burning; itching; irritation; burning.
Miscellaneous
Body pain; fever; chills.
Precautions
Pregnancy
Category C . Avoid during first trimester because of absorption possibility.
Lactation
Undetermined.
Children
Safety and efficacy not established.
Recurrent infections
May indicate underlying medical cause, including diabetes or HIV infection.
Patient Information
- Instruct patient to complete full course of therapy. This medication must be used continuously even through menses.
- Alert patient to potential side effects of vulvovaginal itching or burning, head or body aches. Advise patient to discontinue medication and notify health care provider if irritation occurs.
- Instruct patient to insert applicator high into vagina.
- Wash hands before and after application. Also, maintain external clean genitalia but avoid use of douches or other vaginal OTC products while using the medication.
- Advise patient to wash applicator with mild soap and rinse thoroughly.
- Caution patient to refrain from sexual intercourse during course of therapy in order to help to prevent reinfection.
- Advise patient that sanitary napkin or minipad may be used to prevent stains on clothing.
- Instruct patient to consult with health care provider if infection recurs. Diabetes, AIDS, and chronic antibiotic or steroid therapy place patient at increased risk for recurrent infection.
- Explain that ingredients in product may interact with latex and weaken latex condoms and diaphragms. Advise patient to avoid use of these forms of birth control for 72 h after application of medication.
 |
Link to Page |  |
Print Page |  |
Email Page |  | Add to List |
More Terconazole resources:
Terazol 3 Vaginal - Includes detailed dosage instructions.
